Diabetes is a complex disease

A complex disease dependent on self-care with all kinds of factors affecting the blood glucose.

A New Paradigm for Diabetes Care

Insulin was discovered a hundred years ago, and before 1921 it was exceptional for people with Type 1 diabetes to live more than two years. Insulin is one of the twentieth century’s greatest medical discoveries and is still today the only effective treatment for people with Type 1 diabetes.

In the 1980s, genetically engineered preparations appeared on the market that resembled the body’s own insulin with both short- and long-acting varieties. Around this time, the first insulin pumps were introduced.

In the late 1990s and early 2000s, blood glucose monitoring entered the market with CGM-sensors, which enabled more self-care for people with type 1 diabetes. Today, with data from the CGM-sensors, there is a data and decision overload for the healthcare providers. The patients have to analyze continuous data manually to make daily decisions. Complicated data analysis and physiological modeling are issues as well.

Our solution to this data overload is a clinically validated digital service that generates automated analysis, identification of root causes, and treatment recommendations based on machine learning. DDAnalytics see this as a paradigm shift where we use continuous data to provide better care and decision support for healthcare providers and people living with diabetes.

This is diabetes 3.0.  


In Sweden, about 50 000 people live with type 1 diabetes, and a majority of them use CGM/FGM. Globally, 2 million people use CGM/FGM. In addition, more than 6 million people with type 1 diabetes depend on insulin treatment to survive and need to measure their blood sugar repeatedly to control the treatment, and incorrect dosages can be directly fatal.

Type 1

Globally, 6 million people are living with type 1 diabetes. In Sweden, the number is 50 000 people, and a majority use CGM/FGM who all depend on insulin treatment for their survival. 

  • Autoimmune disease
  • Loss of endogenous insulin production
  • It affects children, adolescents, and adults
  • Solely dependent on exogenous insulin treatment
  • Insulin is delivered via an insulin pen or pump.

Type 2

Globally, 460 million people are living with type 2 diabetes. Approximately four percent of the Swedish population has type 2 diabetes, and among those over the age of 75, at least ten percent have the disease.

  • Life-style related and hereditary disease
  • Insulin resistance is the hallmark of the disease
  • It affects mainly adults but in increasing numbers also children
  • Oral antidiabetic drugs
  • Exogenous insulin treatment in 20-30% of all patients

Acute & Long-term Complications

For both type 1 and type 2 diabetes, the disease includes several acute and long-term complications.

Acute complications can cause unconsciousness, coma, and death. Long-term complications can cause heart disease, cerebrovascular disease, kidney failure, blindness, and premature death. 

Our mission is to provide innovative and data-driven analysis services that meet the needs of patients and healthcare providers.